ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Dr. Reddy’s Laboratories, in India, and Merck Serono, a division of Germany’s Merck KGaA, will jointly develop generic biologic, or biosimilar, drugs. They will focus primarily on developing, manufacturing, and selling monoclonal antibodies for oncology purposes. The partners will share R&D costs and divide up worldwide commercial activities. Dr. Reddy’s will handle early product development, including Phase I clinical trials. After that, Merck Serono will assume manufacturing and development through Phase III.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter